{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T06:53:37Z","timestamp":1772348017861,"version":"3.50.1"},"reference-count":11,"publisher":"Springer Science and Business Media LLC","issue":"11","license":[{"start":{"date-parts":[[2025,6,20]],"date-time":"2025-06-20T00:00:00Z","timestamp":1750377600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,6,20]],"date-time":"2025-06-20T00:00:00Z","timestamp":1750377600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Dig Dis Sci"],"published-print":{"date-parts":[[2025,11]]},"DOI":"10.1007\/s10620-025-09177-7","type":"journal-article","created":{"date-parts":[[2025,6,20]],"date-time":"2025-06-20T11:41:38Z","timestamp":1750419698000},"page":"3603-3605","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Second-Line but Not Second Rate: Fibrates for the Treatment of Patients with Primary Biliary Cholangitis"],"prefix":"10.1007","volume":"70","author":[{"given":"Mark W.","family":"Russo","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,6,20]]},"reference":[{"key":"9177_CR1","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1016\/j.cld.2023.06.005","volume":"28","author":"MS Faisal","year":"2024","unstructured":"Faisal MS, Gonzalez HC, Gordon SC. Primary biliary cholangitis-Epidemiology, diagnosis and presentation. Clin Liv Dis 2024;28:63\u201377.","journal-title":"Clin Liv Dis"},{"key":"9177_CR2","doi-asserted-by":"publisher","first-page":"601","DOI":"10.1309\/AJCPQV4A7QAEEFEV","volume":"144","author":"MM Tana","year":"2015","unstructured":"Tana MM, Shums Z, Milo J et al. The significance of autoantibody changes over time in primary biliary cirrhosis. Am J Clin Pathol 2015;144:601\u2013606.","journal-title":"Am J Clin Pathol"},{"key":"9177_CR3","doi-asserted-by":"publisher","first-page":"357","DOI":"10.1016\/j.jhep.2019.04.001","volume":"71","author":"MH Harms","year":"2019","unstructured":"Harms MH, van Buuren HR, Corpechot C, Thorburn D, Janssen HLA, Lindor KD et al. Ursodeoxcycholic acid therapy and liver transplant-free survival in patients with primary biliary cholangitis. J Hepatol 2019;71:357\u2013365.","journal-title":"J Hepatol"},{"key":"9177_CR4","first-page":"93","volume":"17","author":"AF Gulamhusein","year":"2020","unstructured":"Gulamhusein AF, Hirschfield GM. Primary biliary cholangitis: pathogenesis and therapeutic opportunities. Nature Reviews: Gastroenterology & Hepatology 2020;17:93\u2013110.","journal-title":"Nature Reviews: Gastroenterology & Hepatology"},{"key":"9177_CR5","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1586\/17512433.2015.1092381","volume":"9","author":"PJ Trivedi","year":"2016","unstructured":"Trivedi PJ, Hirschfield GM, Gerswhin ME. Obeticholic acid for the treatment of primary biliary cirrhosis. Expert Rev Clin Pharmacol 2016;9:13\u201326.","journal-title":"Expert Rev Clin Pharmacol"},{"key":"9177_CR6","doi-asserted-by":"publisher","first-page":"631","DOI":"10.1056\/NEJMoa1509840","volume":"375","author":"F Nevens","year":"2016","unstructured":"Nevens F, Andreone P, Mazella G, Strasser SI, Bowlus C, Invernizzi P et al. A placebo-controlled trial of obeticholic acid in primary biliary cholangitis. N Engl J Med 2016;375:631\u2013643.","journal-title":"N Engl J Med"},{"key":"9177_CR7","doi-asserted-by":"publisher","first-page":"2171","DOI":"10.1056\/NEJMoa1714519","volume":"378","author":"C Corpechot","year":"2018","unstructured":"Corpechot C, Chazouill\u00e8res O, Rousseau A, Le Gruyer A, Habersetzer F, Mathurin P et al. A placebo-controlled trial of bezafibrate in primary biliary cholangitis. N Engl J Med 2018;378:2171\u20132181.","journal-title":"N Engl J Med"},{"key":"9177_CR8","doi-asserted-by":"publisher","first-page":"283","DOI":"10.1111\/apt.13465","volume":"43","author":"AC Cheung","year":"2016","unstructured":"Cheung AC, Lapointe-Shaw L, Kowgier M, Meza-Cardona J, Hirschfield GM, Janssen HL et al. Combined ursodeoxycholic acid (UDCA) and fenofibrate in primary biliary cholangitis patients with incomplete UDCA response may improve outcomes. Aliment Pharmacol Ther 2016;43:283\u2013293.","journal-title":"Aliment Pharmacol Ther"},{"key":"9177_CR9","doi-asserted-by":"publisher","unstructured":"De Abreu ES, Reginato PH, Pitanga JFJ, Borges PN, Soret PA, Corpechot C, et al. Obeticholic acid vs fibrates as second-line therapy for primary biliary cholangitis: Systematic review and meta-analysis. Dig Dis Sci 2025. https:\/\/doi.org\/10.1007\/s10620-025-09044-5","DOI":"10.1007\/s10620-025-09044-5"},{"key":"9177_CR10","doi-asserted-by":"publisher","first-page":"795","DOI":"10.1056\/NEJMoa2306185","volume":"390","author":"KV Kowdley","year":"2024","unstructured":"Kowdley KV, Bowlus CL, Levy C, Akarc US, Lavares-da-Silva MR, Andreone P et al. Efficacy and safety of elafibrinor in primary cholangitis. N Engl J Med 2024;390:795\u2013805.","journal-title":"N Engl J Med"},{"key":"9177_CR11","doi-asserted-by":"publisher","first-page":"783","DOI":"10.1056\/NEJMoa2312100","volume":"390","author":"GM Hirschfield","year":"2024","unstructured":"Hirschfield GM, Bowlus CL, Mayo MJ, Kremer AI, Vierling JM, Kowdley KV et al. A phase 3 trial of seladelpar in primary biliary cholangitis. N Engl J Med 2024;390:783\u2013794.","journal-title":"N Engl J Med"}],"container-title":["Digestive Diseases and Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10620-025-09177-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10620-025-09177-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10620-025-09177-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,18]],"date-time":"2025-11-18T04:53:36Z","timestamp":1763441616000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10620-025-09177-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6,20]]},"references-count":11,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2025,11]]}},"alternative-id":["9177"],"URL":"https:\/\/doi.org\/10.1007\/s10620-025-09177-7","relation":{},"ISSN":["0163-2116","1573-2568"],"issn-type":[{"value":"0163-2116","type":"print"},{"value":"1573-2568","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,6,20]]},"assertion":[{"value":"19 May 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 June 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 June 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"This content has been made available to all.","name":"free","label":"Free to read"}]}}